Ahlquist, David A.
Article History
Received: 7 June 2018
Revised: 14 August 2018
Accepted: 16 August 2018
First Online: 29 October 2018
Competing interests
: D.A.A. is co-inventor of the multi-target stool DNA test (Cologuard) and receives a portion of royalties from Exact Sciences to Mayo Clinic in accordance with Mayo Clinic policy. Mayo Clinic has an umbrella agreement with Exact Sciences to co-develop next generation molecular diagnostics for cancer detection; D.A.A. and his research team have contributed substantial intellectual property in this effort that has been licensed to Exact Sciences. The views expressed in this article are those of D.A.A. and do not reflect inputs from either Mayo Clinic or Exact Sciences.